Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
University of Medicine and Dentistry of New Jersey
With
OBJECTIVES: Primary * To determine the recommended phase II dose of hydroxychloroquine and carboplatin in combination with paclitaxel and bevacizumab in patients with advanced recurrent non-small cell lung cancer. (Phase I) * To assess the antitumor activity, as measured by tumor response rate, of this regimen in these patients. (Phase II) Secondary * To measure time to progression, progression-free survival, and overall survival of these patients. * To assess the incidence of toxicity of this regimen in these patients. OUTLINE: This is a multicenter study. This is a phase I, dose-escalation study of carboplatin and hydroxychloroquine followed by a phase II study. Patients receive paclitaxel IV over 3 hours, carboplatin IV over 15-30 minutes, and bevacizumab IV over 90 minutes on day 1 and oral hydroxychloroquine on days 1-21. Treatment repeats every 21 days for a total of 4 courses. Patients then receive bevacizumab IV over 30-90 minutes every 21 days and oral hydroxychloroquine daily for up to 1 year in the absence of disease progression or unacceptable toxicity. After completion of study therapy, patients are followed every 6 months.
Age
18–120
Sex
ALL
Healthy volunteers
Not accepted
